alfuzosin (Rx)

Brand and Other Names:Alfutral, UroXatral, more...Xatral
  • Print

Dosing & Uses

AdultPediatric

Dosage Forms & Strengths

tablet, extended release

  • 10mg

Benign Prostatic Hyperplasia (BPH)

10 mg PO qDay taken after same meal

Safety & efficacy not established

Next:

Interactions

Interaction Checker

and alfuzosin

No Results

     activity indicator 
    No Interactions Found
    Interactions Found

    Contraindicated

      Serious - Use Alternative

        Significant - Monitor Closely

          Minor

            All Interactions Sort By:
             activity indicator 

            Contraindicated (19)

            • atazanavir

              atazanavir will increase the level or effect of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated.

            • chloramphenicol

              chloramphenicol will increase the level or effect of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated.

            • cobicistat

              cobicistat will increase the level or effect of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Potential for increased alfuzosin concentrations, which can result in serious or life threatening reactions such as hypotension

            • darunavir

              darunavir will increase the level or effect of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Potential for serious and/or life-threatening reactions.

            • elvitegravir/cobicistat/emtricitabine/tenofovir DF

              elvitegravir/cobicistat/emtricitabine/tenofovir DF increases levels of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Cobicistat is a CYP3A4 inhibitor; contraindicated with CYP3A4 substrates for which elevated plasma concentrations are associated with serious and/or life-threatening events.

            • fosamprenavir

              fosamprenavir will increase the level or effect of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated.

            • idelalisib

              idelalisib will increase the level or effect of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated.

            • indinavir

              indinavir will increase the level or effect of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated.

            • itraconazole

              itraconazole increases levels of alfuzosin by decreasing metabolism. Contraindicated.

            • ketoconazole

              ketoconazole increases levels of alfuzosin by decreasing metabolism. Contraindicated.

            • lefamulin

              lefamulin will increase the level or effect of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Lefamulin is contraindicated with CYP3A substrates know to prolong the QT interval.

            • lopinavir

              lopinavir will increase the level or effect of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated.

            • mifepristone

              mifepristone will increase the level or effect of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated.

            • nefazodone

              nefazodone will increase the level or effect of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated.

            • nelfinavir

              nelfinavir will increase the level or effect of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated.

            • ombitasvir/paritaprevir/ritonavir & dasabuvir

              ombitasvir/paritaprevir/ritonavir & dasabuvir will increase the level or effect of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Increased risk for hypotensio

            • ritonavir

              ritonavir will increase the level or effect of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated.

            • saquinavir

              saquinavir increases levels of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Potential for increased toxicity. .

            • tipranavir

              tipranavir increases levels of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Potential for increased toxicity. Tipranavir is used with ritonavir (boosted therapy) which is a potent CYP3A4 inhibitor.

            Serious - Use Alternative (24)

            • abametapir

              abametapir will increase the level or effect of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. For 2 weeks after abametapir application, avoid taking drugs that are CYP3A4 substrates. If not feasible, avoid use of abametapir.

            • apalutamide

              apalutamide will decrease the level or effect of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Coadministration of apalutamide, a strong CYP3A4 inducer, with drugs that are CYP3A4 substrates can result in lower exposure to these medications. Avoid or substitute another drug for these medications when possible. Evaluate for loss of therapeutic effect if medication must be coadministered. Adjust dose according to prescribing information if needed.

            • efavirenz

              efavirenz will decrease the level or effect of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.

            • enzalutamide

              enzalutamide will decrease the level or effect of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.

            • etravirine

              etravirine will decrease the level or effect of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.

            • glasdegib

              alfuzosin and glasdegib both increase QTc interval. Avoid or Use Alternate Drug. If coadministration unavoidable, monitor for increased risk of QTc interval prolongation.

            • hydroxychloroquine sulfate

              hydroxychloroquine sulfate and alfuzosin both increase QTc interval. Avoid or Use Alternate Drug.

            • inotuzumab

              inotuzumab and alfuzosin both increase QTc interval. Avoid or Use Alternate Drug. If unable to avoid concomitant use, obtain ECGs and electrolytes before and after initiation of any drug known to prolong QTc, and periodically monitor as clinically indicated during treatment.

            • isoniazid

              isoniazid will increase the level or effect of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.

            • ivosidenib

              ivosidenib and alfuzosin both increase QTc interval. Avoid or Use Alternate Drug. Avoid coadministration of QTc prolonging drugs with ivosidenib or replace with alternate therapies. If coadministration of a QTc prolonging drug is unavoidable, monitor for increased risk of QTc interval prolongation.

              ivosidenib will decrease the level or effect of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Avoid coadministration of sensitive CYP3A4 substrates with ivosidenib or replace with alternate therapies. If coadministration is unavoidable, monitor patients for loss of therapeutic effect of these drugs.

            • lonafarnib

              lonafarnib will increase the level or effect of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Avoid coadministration with sensitive CYP3A substrates. If coadministration unavoidable, monitor for adverse reactions and reduce CYP3A substrate dose in accordance with product labeling.

            • macimorelin

              macimorelin and alfuzosin both increase QTc interval. Avoid or Use Alternate Drug. Macimorelin causes an increase of ~11 msec in the corrected QT interval. Avoid coadministration with drugs that prolong QT interval, which could increase risk for developing torsade de pointes-type ventricular tachycardia. Allow sufficient washout time of drugs that are known to prolong the QT interval before administering macimorelin.

            • mifepristone

              mifepristone and alfuzosin both increase QTc interval. Avoid or Use Alternate Drug. Use alternatives if available

            • ondansetron

              alfuzosin and ondansetron both increase QTc interval. Avoid or Use Alternate Drug. Avoid with congenital long QT syndrome; ECG monitoring recommended with concomitant medications that prolong QT interval, electrolyte abnormalities, CHF, or bradyarrhythmias.

            • panobinostat

              alfuzosin and panobinostat both increase QTc interval. Avoid or Use Alternate Drug. Panobinostat is known to significantly prolong QT interval. Panobinostat prescribing information states use with drugs known to prolong QTc is not recommended.

            • quinine

              alfuzosin and quinine both increase QTc interval. Avoid or Use Alternate Drug.

            • sildenafil

              sildenafil increases effects of alfuzosin by pharmacodynamic synergism. Avoid or Use Alternate Drug. Risk of hypotension; separate sildenafil >25mg from alpha blocker by 4hr.

            • tamsulosin

              alfuzosin, tamsulosin. Either increases effects of the other by additive vasodilation. Avoid or Use Alternate Drug. Risk of hypotension.

            • toremifene

              alfuzosin and toremifene both increase QTc interval. Avoid or Use Alternate Drug. Concurrent use of toremifene with agents causing QT prolongation should be avoided. If concomitant use is required it's recommended that toremifene be interrupted. If interruption not possible, patients requiring therapy with a drug that prolongs QT should be closely monitored. ECGs should be obtained for high risk patients.

            • umeclidinium bromide/vilanterol inhaled

              alfuzosin increases toxicity of umeclidinium bromide/vilanterol inhaled by QTc interval. Avoid or Use Alternate Drug. Exercise extreme caution when vilanterol coadministered with drugs that prolong QTc interval; adrenergic agonist effects on the cardiovascular system may be potentiated.

            • vardenafil

              vardenafil increases effects of alfuzosin by pharmacodynamic synergism. Contraindicated. Risk of hypotension.

            • vilanterol/fluticasone furoate inhaled

              alfuzosin increases toxicity of vilanterol/fluticasone furoate inhaled by QTc interval. Avoid or Use Alternate Drug. Exercise extreme caution when vilanterol coadministered with drugs that prolong QTc interval; adrenergic agonist effects on the cardiovascular system may be potentiated.

            • voxelotor

              voxelotor will increase the level or effect of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Voxelotor increases systemic exposure of sensitive CYP3A4 substrates. Avoid coadministration with sensitive CYP3A4 substrates with a narrow therapeutic index. Consider dose reduction of the sensitive CYP3A4 substrate(s) if unable to avoid.

            • yohimbe

              yohimbe increases effects of alfuzosin by pharmacodynamic synergism. Contraindicated.

            Monitor Closely (213)

            • acebutolol

              alfuzosin and acebutolol both increase anti-hypertensive channel blocking. Modify Therapy/Monitor Closely. The severity and duration of hypotension following the first dose of Alfuzosin may be enhanced.

            • aceclofenac

              aceclofenac decreases effects of alfuzosin by pharmacodynamic antagonism. Use Caution/Monitor. NSAIDs decrease prostaglandin synthesis.

            • acemetacin

              acemetacin decreases effects of alfuzosin by pharmacodynamic antagonism. Use Caution/Monitor. NSAIDs decrease prostaglandin synthesis.

            • aldesleukin

              aldesleukin increases effects of alfuzosin by pharmacodynamic synergism. Use Caution/Monitor. Risk of hypotension.

            • amifostine

              amifostine, alfuzosin. Either increases effects of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Coadministration with blood pressure lowering agents may increase the risk and severity of hypotension associated with amifostine. When amifostine is used at chemotherapeutic doses, withhold blood pressure lowering medications for 24 hr prior to amifostine; if blood pressure lowering medication cannot be withheld, do not administer amifostine.

            • amitriptyline

              amitriptyline and alfuzosin both increase QTc interval. Use Caution/Monitor.

            • amlodipine

              alfuzosin and amlodipine both increase anti-hypertensive channel blocking. Use Caution/Monitor.

            • apomorphine

              apomorphine and alfuzosin both increase QTc interval. Use Caution/Monitor.

            • arformoterol

              arformoterol and alfuzosin both increase QTc interval. Use Caution/Monitor.

            • artemether

              artemether and alfuzosin both increase QTc interval. Use Caution/Monitor.

            • asenapine

              alfuzosin and asenapine both increase anti-hypertensive channel blocking. Use Caution/Monitor.

            • aspirin

              aspirin decreases effects of alfuzosin by pharmacodynamic antagonism. Use Caution/Monitor. NSAIDs decrease prostaglandin synthesis.

            • aspirin rectal

              aspirin rectal decreases effects of alfuzosin by pharmacodynamic antagonism. Use Caution/Monitor. NSAIDs decrease prostaglandin synthesis.

            • aspirin/citric acid/sodium bicarbonate

              aspirin/citric acid/sodium bicarbonate decreases effects of alfuzosin by pharmacodynamic antagonism. Use Caution/Monitor. NSAIDs decrease prostaglandin synthesis.

            • atenolol

              alfuzosin and atenolol both increase anti-hypertensive channel blocking. Modify Therapy/Monitor Closely.

            • avanafil

              avanafil increases effects of alfuzosin by pharmacodynamic synergism. Use Caution/Monitor. Risk of hypotension.

            • azithromycin

              azithromycin and alfuzosin both increase QTc interval. Use Caution/Monitor.

            • bedaquiline

              alfuzosin and bedaquiline both increase QTc interval. Modify Therapy/Monitor Closely. ECG should be monitored closely

            • benazepril

              benazepril, alfuzosin. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Exaggerated first dose hypotensive response.

              alfuzosin increases effects of benazepril by Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Increased risk of hypotension.

            • betaxolol

              alfuzosin and betaxolol both increase anti-hypertensive channel blocking. Modify Therapy/Monitor Closely.

            • bisoprolol

              alfuzosin and bisoprolol both increase anti-hypertensive channel blocking. Modify Therapy/Monitor Closely.

            • captopril

              captopril, alfuzosin. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Exaggerated first dose hypotensive response.

              alfuzosin increases effects of captopril by pharmacodynamic synergism. Use Caution/Monitor. Both drugs decrease blood pressure. Monitor blood pressure.

            • carbamazepine

              carbamazepine will decrease the level or effect of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.

            • carbidopa

              carbidopa increases effects of alfuzosin by pharmacodynamic synergism. Use Caution/Monitor. Monitor for hypotension.

            • carvedilol

              alfuzosin and carvedilol both increase anti-hypertensive channel blocking. Modify Therapy/Monitor Closely.

            • celecoxib

              celecoxib decreases effects of alfuzosin by pharmacodynamic antagonism. Use Caution/Monitor. NSAIDs decrease prostaglandin synthesis.

            • celiprolol

              alfuzosin and celiprolol both increase anti-hypertensive channel blocking. Modify Therapy/Monitor Closely.

            • cenobamate

              cenobamate will decrease the level or effect of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Increase dose of CYP3A4 substrate, as needed, when coadministered with cenobamate.

            • chlorpromazine

              chlorpromazine and alfuzosin both increase QTc interval. Use Caution/Monitor.

            • choline magnesium trisalicylate

              choline magnesium trisalicylate decreases effects of alfuzosin by pharmacodynamic antagonism. Use Caution/Monitor. NSAIDs decrease prostaglandin synthesis.

            • cimetidine

              cimetidine will increase the level or effect of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.

            • ciprofloxacin

              ciprofloxacin and alfuzosin both increase QTc interval. Use Caution/Monitor.

            • citalopram

              citalopram and alfuzosin both increase QTc interval. Use Caution/Monitor.

            • clarithromycin

              clarithromycin will increase the level or effect of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.

              clarithromycin and alfuzosin both increase QTc interval. Use Caution/Monitor.

            • clevidipine

              alfuzosin and clevidipine both increase anti-hypertensive channel blocking. Use Caution/Monitor.

            • clomipramine

              clomipramine and alfuzosin both increase QTc interval. Use Caution/Monitor.

            • clozapine

              clozapine and alfuzosin both increase QTc interval. Use Caution/Monitor.

            • crizotinib

              crizotinib increases levels of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Dose reduction may be needed for coadministered drugs that are predominantly metabolized by CYP3A.

              crizotinib and alfuzosin both increase QTc interval. Use Caution/Monitor.

            • crofelemer

              crofelemer increases levels of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Crofelemer has the potential to inhibit CYP3A4 at concentrations expected in the gut; unlikely to inhibit systemically because minimally absorbed.

            • dabrafenib

              dabrafenib will decrease the level or effect of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely.

            • dasatinib

              dasatinib and alfuzosin both increase QTc interval. Use Caution/Monitor.

            • deferasirox

              deferasirox will decrease the level or effect of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.

            • degarelix

              degarelix and alfuzosin both increase QTc interval. Use Caution/Monitor.

            • delafloxacin

              delafloxacin and alfuzosin both increase QTc interval. Use Caution/Monitor.

            • desipramine

              desipramine and alfuzosin both increase QTc interval. Use Caution/Monitor.

            • diclofenac

              diclofenac decreases effects of alfuzosin by pharmacodynamic antagonism. Use Caution/Monitor. NSAIDs decrease prostaglandin synthesis.

            • diflunisal

              diflunisal decreases effects of alfuzosin by pharmacodynamic antagonism. Use Caution/Monitor. NSAIDs decrease prostaglandin synthesis.

            • diltiazem

              diltiazem will increase the level or effect of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Increased exposure to alfuzosin may be expected when alfuzosin is concomitantly used with diltiazem. Monitor pulse and blood pressure.

            • dofetilide

              dofetilide increases toxicity of alfuzosin by QTc interval. Use Caution/Monitor.

            • dolasetron

              dolasetron and alfuzosin both increase QTc interval. Use Caution/Monitor.

            • doxazosin

              alfuzosin and doxazosin both increase anti-hypertensive channel blocking. Use Caution/Monitor.

            • droperidol

              droperidol and alfuzosin both increase QTc interval. Use Caution/Monitor.

            • duvelisib

              duvelisib will increase the level or effect of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Coadministration with duvelisib increases AUC of a sensitive CYP3A4 substrate which may increase the risk of toxicities of these drugs. Consider reducing the dose of the sensitive CYP3A4 substrate and monitor for signs of toxicities of the coadministered sensitive CYP3A substrate.

            • elagolix

              elagolix will decrease the level or effect of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Elagolix is a weak-to-moderate CYP3A4 inducer. Monitor CYP3A substrates if coadministered. Consider increasing CYP3A substrate dose if needed.

            • enalapril

              enalapril, alfuzosin. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Exaggerated first dose hypotensive response.

            • encorafenib

              encorafenib, alfuzosin. affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Encorafenib both inhibits and induces CYP3A4 at clinically relevant plasma concentrations. Coadministration of encorafenib with sensitive CYP3A4 substrates may result in increased toxicity or decreased efficacy of these agents.

              encorafenib and alfuzosin both increase QTc interval. Use Caution/Monitor.

            • eribulin

              eribulin and alfuzosin both increase QTc interval. Use Caution/Monitor.

            • erythromycin base

              erythromycin base will increase the level or effect of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.

              erythromycin base and alfuzosin both increase QTc interval. Use Caution/Monitor.

            • erythromycin ethylsuccinate

              erythromycin ethylsuccinate will increase the level or effect of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.

              erythromycin ethylsuccinate and alfuzosin both increase QTc interval. Use Caution/Monitor.

            • erythromycin lactobionate

              erythromycin lactobionate will increase the level or effect of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.

              erythromycin lactobionate and alfuzosin both increase QTc interval. Use Caution/Monitor.

            • erythromycin stearate

              erythromycin stearate will increase the level or effect of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.

              erythromycin stearate and alfuzosin both increase QTc interval. Use Caution/Monitor.

            • escitalopram

              escitalopram and alfuzosin both increase QTc interval. Use Caution/Monitor.

            • esmolol

              alfuzosin and esmolol both increase anti-hypertensive channel blocking. Modify Therapy/Monitor Closely. The severity and duration of hypotension following the first dose of Alfuzosin may be enhanced.

            • etodolac

              etodolac decreases effects of alfuzosin by pharmacodynamic antagonism. Use Caution/Monitor. NSAIDs decrease prostaglandin synthesis.

            • fedratinib

              fedratinib will increase the level or effect of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Adjust dose of drugs that are CYP3A4 substrates as necessary.

            • felodipine

              alfuzosin and felodipine both increase anti-hypertensive channel blocking. Use Caution/Monitor.

            • fenoprofen

              fenoprofen decreases effects of alfuzosin by pharmacodynamic antagonism. Use Caution/Monitor. NSAIDs decrease prostaglandin synthesis.

            • fluoxetine

              alfuzosin and fluoxetine both increase QTc interval. Modify Therapy/Monitor Closely.

              fluoxetine and alfuzosin both increase QTc interval. Use Caution/Monitor.

            • fluphenazine

              fluphenazine and alfuzosin both increase QTc interval. Use Caution/Monitor.

            • flurbiprofen

              flurbiprofen decreases effects of alfuzosin by pharmacodynamic antagonism. Use Caution/Monitor. NSAIDs decrease prostaglandin synthesis.

            • fluvoxamine

              fluvoxamine and alfuzosin both increase QTc interval. Use Caution/Monitor.

            • formoterol

              formoterol and alfuzosin both increase QTc interval. Use Caution/Monitor.

            • foscarnet

              foscarnet and alfuzosin both increase QTc interval. Use Caution/Monitor.

            • fosinopril

              fosinopril, alfuzosin. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Exaggerated first dose hypotensive response.

            • fostemsavir

              alfuzosin and fostemsavir both increase QTc interval. Use Caution/Monitor. QTc prolongation reported with higher than recommended doses of fostemsavir.

            • gemifloxacin

              gemifloxacin and alfuzosin both increase QTc interval. Use Caution/Monitor.

            • gemtuzumab

              alfuzosin and gemtuzumab both increase QTc interval. Use Caution/Monitor.

            • goserelin

              goserelin increases toxicity of alfuzosin by QTc interval. Use Caution/Monitor.

            • haloperidol

              haloperidol and alfuzosin both increase QTc interval. Use Caution/Monitor.

            • histrelin

              histrelin increases toxicity of alfuzosin by QTc interval. Use Caution/Monitor.

            • ibuprofen

              ibuprofen decreases effects of alfuzosin by pharmacodynamic antagonism. Use Caution/Monitor. NSAIDs decrease prostaglandin synthesis.

            • ibuprofen IV

              ibuprofen IV decreases effects of alfuzosin by pharmacodynamic antagonism. Use Caution/Monitor. NSAIDs decrease prostaglandin synthesis.

            • iloperidone

              iloperidone increases effects of alfuzosin by pharmacodynamic synergism. Use Caution/Monitor.

              iloperidone increases effects of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Iloperidone is a time-dependent CYP3A inhibitor and may lead to increased plasma levels of drugs predominantly eliminated by CYP3A4.

            • imidapril

              imidapril, alfuzosin. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Exaggerated first dose hypotensive response.

            • indacaterol, inhaled

              indacaterol, inhaled and alfuzosin both increase QTc interval. Use Caution/Monitor. Drugs that are known to prolong the QTc interval may have an increased the risk of ventricular arrhythmias.

            • indapamide

              indapamide and alfuzosin both increase QTc interval. Use Caution/Monitor.

            • indomethacin

              indomethacin decreases effects of alfuzosin by pharmacodynamic antagonism. Use Caution/Monitor. NSAIDs decrease prostaglandin synthesis.

            • isradipine

              alfuzosin and isradipine both increase anti-hypertensive channel blocking. Use Caution/Monitor.

              isradipine and alfuzosin both increase QTc interval. Use Caution/Monitor.

            • istradefylline

              istradefylline will increase the level or effect of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Istradefylline 40 mg/day increased peak levels and AUC of CYP3A4 substrates in clinical trials. This effect was not observed with istradefylline 20 mg/day. Consider dose reduction of sensitive CYP3A4 substrates.

            • ketoconazole

              ketoconazole will increase the level or effect of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.

            • ketoprofen

              ketoprofen decreases effects of alfuzosin by pharmacodynamic antagonism. Use Caution/Monitor. NSAIDs decrease prostaglandin synthesis.

            • ketorolac

              ketorolac decreases effects of alfuzosin by pharmacodynamic antagonism. Use Caution/Monitor. NSAIDs decrease prostaglandin synthesis.

            • ketorolac intranasal

              ketorolac intranasal decreases effects of alfuzosin by pharmacodynamic antagonism. Use Caution/Monitor. NSAIDs decrease prostaglandin synthesis.

            • labetalol

              alfuzosin and labetalol both increase anti-hypertensive channel blocking. Modify Therapy/Monitor Closely.

            • lapatinib

              lapatinib and alfuzosin both increase QTc interval. Use Caution/Monitor.

            • lenvatinib

              alfuzosin and lenvatinib both increase QTc interval. Use Caution/Monitor. Lenvatinib prescribing information recommends monitoring ECG closely when coadministered with QT prolonging drugs.

            • letermovir

              letermovir increases levels of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.

            • leuprolide

              leuprolide increases toxicity of alfuzosin by QTc interval. Use Caution/Monitor. Increases risk of torsades de pointes.

            • levofloxacin

              levofloxacin and alfuzosin both increase QTc interval. Use Caution/Monitor.

            • lisinopril

              lisinopril, alfuzosin. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Exaggerated first dose hypotensive response.

            • lofexidine

              lofexidine and alfuzosin both increase QTc interval. Use Caution/Monitor.

            • lopinavir

              lopinavir and alfuzosin both increase QTc interval. Use Caution/Monitor.

            • lorlatinib

              lorlatinib will decrease the level or effect of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.

            • lornoxicam

              lornoxicam decreases effects of alfuzosin by pharmacodynamic antagonism. Use Caution/Monitor. NSAIDs decrease prostaglandin synthesis.

            • lumefantrine

              lumefantrine and alfuzosin both increase QTc interval. Use Caution/Monitor.

            • lurasidone

              lurasidone increases effects of alfuzosin by Other (see comment). Use Caution/Monitor. Comment: Potential for increased risk of hypotension with concurrent use. Monitor blood pressure and adjust dose of antihypertensive agent as needed.

            • maprotiline

              maprotiline and alfuzosin both increase QTc interval. Use Caution/Monitor.

            • maraviroc

              maraviroc, alfuzosin. Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of orthostatic hypotension.

            • meclofenamate

              meclofenamate decreases effects of alfuzosin by pharmacodynamic antagonism. Use Caution/Monitor. NSAIDs decrease prostaglandin synthesis.

            • mefenamic acid

              mefenamic acid decreases effects of alfuzosin by pharmacodynamic antagonism. Use Caution/Monitor. NSAIDs decrease prostaglandin synthesis.

            • mefloquine

              mefloquine and alfuzosin both increase QTc interval. Use Caution/Monitor.

            • meloxicam

              meloxicam decreases effects of alfuzosin by pharmacodynamic antagonism. Use Caution/Monitor. NSAIDs decrease prostaglandin synthesis.

            • methadone

              methadone and alfuzosin both increase QTc interval. Use Caution/Monitor.

            • metoprolol

              alfuzosin and metoprolol both increase anti-hypertensive channel blocking. Modify Therapy/Monitor Closely.

            • mitotane

              mitotane decreases levels of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Mitotane is a strong inducer of cytochrome P-4503A4; monitor when coadministered with CYP3A4 substrates for possible dosage adjustments.

            • moexipril

              moexipril, alfuzosin. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Exaggerated first dose hypotensive response.

            • moxifloxacin

              moxifloxacin and alfuzosin both increase QTc interval. Use Caution/Monitor.

            • moxisylyte

              alfuzosin and moxisylyte both increase anti-hypertensive channel blocking. Use Caution/Monitor.

            • nabumetone

              nabumetone decreases effects of alfuzosin by pharmacodynamic antagonism. Use Caution/Monitor. NSAIDs decrease prostaglandin synthesis.

            • nadolol

              alfuzosin and nadolol both increase anti-hypertensive channel blocking. Modify Therapy/Monitor Closely.

            • naproxen

              naproxen decreases effects of alfuzosin by pharmacodynamic antagonism. Use Caution/Monitor. NSAIDs decrease prostaglandin synthesis.

            • nebivolol

              alfuzosin and nebivolol both increase anti-hypertensive channel blocking. Modify Therapy/Monitor Closely.

            • nevirapine

              nevirapine will decrease the level or effect of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.

            • nicardipine

              alfuzosin and nicardipine both increase anti-hypertensive channel blocking. Use Caution/Monitor.

            • nifedipine

              alfuzosin and nifedipine both increase anti-hypertensive channel blocking. Use Caution/Monitor.

            • nilotinib

              nilotinib and alfuzosin both increase QTc interval. Use Caution/Monitor.

            • nisoldipine

              alfuzosin and nisoldipine both increase anti-hypertensive channel blocking. Use Caution/Monitor.

            • nitroglycerin rectal

              nitroglycerin rectal, alfuzosin. Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Observe for possible additive hypotensive effects during concomitant use. .

            • nortriptyline

              nortriptyline and alfuzosin both increase QTc interval. Use Caution/Monitor.

            • octreotide

              octreotide and alfuzosin both increase QTc interval. Use Caution/Monitor.

            • ofloxacin

              ofloxacin and alfuzosin both increase QTc interval. Use Caution/Monitor.

            • olanzapine

              olanzapine and alfuzosin both increase QTc interval. Use Caution/Monitor.

            • olodaterol inhaled

              alfuzosin and olodaterol inhaled both increase QTc interval. Use Caution/Monitor. Drugs that prolong the QTc interval and may potentiate the effects of beta2 agonists on the cardiovascular system; increased risk of ventricular arrhythmias

            • ondansetron

              ondansetron and alfuzosin both increase QTc interval. Use Caution/Monitor.

            • osilodrostat

              osilodrostat and alfuzosin both increase QTc interval. Use Caution/Monitor.

            • osimertinib

              osimertinib and alfuzosin both increase QTc interval. Use Caution/Monitor.

            • oxaliplatin

              oxaliplatin will increase the level or effect of alfuzosin by Other (see comment). Use Caution/Monitor. Monitor for ECG changes if therapy is initiated in patients with drugs known to prolong QT interval.

            • oxaprozin

              oxaprozin decreases effects of alfuzosin by pharmacodynamic antagonism. Use Caution/Monitor. NSAIDs decrease prostaglandin synthesis.

            • oxymetazoline topical

              oxymetazoline topical increases and alfuzosin decreases sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Effect of interaction is not clear, use caution. Use Caution/Monitor.

            • ozanimod

              ozanimod and alfuzosin both increase QTc interval. Modify Therapy/Monitor Closely. The potential additive effects on heart rate, treatment with ozanimod should generally not be initiated in patients who are concurrently treated with QT prolonging drugs with known arrhythmogenic properties.

            • paliperidone

              paliperidone and alfuzosin both increase QTc interval. Use Caution/Monitor.

            • panobinostat

              panobinostat and alfuzosin both increase QTc interval. Use Caution/Monitor.

            • parecoxib

              parecoxib decreases effects of alfuzosin by pharmacodynamic antagonism. Use Caution/Monitor. NSAIDs decrease prostaglandin synthesis.

            • paroxetine

              paroxetine and alfuzosin both increase QTc interval. Use Caution/Monitor.

            • pasireotide

              alfuzosin and pasireotide both increase QTc interval. Modify Therapy/Monitor Closely.

              pasireotide and alfuzosin both increase QTc interval. Use Caution/Monitor.

            • pazopanib

              pazopanib and alfuzosin both increase QTc interval. Use Caution/Monitor.

            • penbutolol

              alfuzosin and penbutolol both increase anti-hypertensive channel blocking. Modify Therapy/Monitor Closely.

            • pentamidine

              pentamidine and alfuzosin both increase QTc interval. Use Caution/Monitor.

            • perindopril

              perindopril, alfuzosin. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Exaggerated first dose hypotensive response.

            • perphenazine

              perphenazine and alfuzosin both increase QTc interval. Use Caution/Monitor.

            • phenoxybenzamine

              alfuzosin and phenoxybenzamine both increase anti-hypertensive channel blocking. Use Caution/Monitor.

            • phentolamine

              alfuzosin and phentolamine both increase anti-hypertensive channel blocking. Use Caution/Monitor.

            • pimavanserin

              pimavanserin and alfuzosin both increase QTc interval. Use Caution/Monitor.

            • pimozide

              pimozide and alfuzosin both increase QTc interval. Use Caution/Monitor.

            • pindolol

              alfuzosin and pindolol both increase anti-hypertensive channel blocking. Modify Therapy/Monitor Closely.

            • piroxicam

              piroxicam decreases effects of alfuzosin by pharmacodynamic antagonism. Use Caution/Monitor. NSAIDs decrease prostaglandin synthesis.

            • pitolisant

              pitolisant and alfuzosin both increase QTc interval. Use Caution/Monitor.

            • posaconazole

              posaconazole and alfuzosin both increase QTc interval. Use Caution/Monitor.

            • prazosin

              alfuzosin and prazosin both increase anti-hypertensive channel blocking. Use Caution/Monitor.

            • procainamide

              procainamide and alfuzosin both increase QTc interval. Use Caution/Monitor.

            • propafenone

              propafenone and alfuzosin both increase QTc interval. Use Caution/Monitor.

            • propranolol

              alfuzosin and propranolol both increase anti-hypertensive channel blocking. Modify Therapy/Monitor Closely. The severity and duration of hypotension following the first dose of Alfuzosin may be enhanced.

            • protriptyline

              protriptyline and alfuzosin both increase QTc interval. Use Caution/Monitor.

            • pseudoephedrine

              pseudoephedrine decreases effects of alfuzosin by sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Use Caution/Monitor.

            • quetiapine

              quetiapine and alfuzosin both increase QTc interval. Use Caution/Monitor.

            • quinapril

              quinapril, alfuzosin. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Exaggerated first dose hypotensive response.

            • quinidine

              quinidine and alfuzosin both increase QTc interval. Use Caution/Monitor.

            • ramipril

              ramipril, alfuzosin. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Exaggerated first dose hypotensive response.

            • ranolazine

              ranolazine and alfuzosin both increase QTc interval. Use Caution/Monitor.

            • ribociclib

              ribociclib and alfuzosin both increase QTc interval. Use Caution/Monitor.

              ribociclib will increase the level or effect of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.

            • rifabutin

              rifabutin will decrease the level or effect of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.

            • rifampin

              rifampin will decrease the level or effect of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.

            • rilpivirine

              rilpivirine and alfuzosin both increase QTc interval. Use Caution/Monitor.

            • risperidone

              risperidone and alfuzosin both increase QTc interval. Use Caution/Monitor.

            • romidepsin

              romidepsin and alfuzosin both increase QTc interval. Use Caution/Monitor.

            • rucaparib

              rucaparib will increase the level or effect of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Adjust dosage of CYP3A4 substrates, if clinically indicated.

            • salicylates (non-asa)

              salicylates (non-asa) decreases effects of alfuzosin by pharmacodynamic antagonism. Use Caution/Monitor. NSAIDs decrease prostaglandin synthesis.

            • salsalate

              salsalate decreases effects of alfuzosin by pharmacodynamic antagonism. Use Caution/Monitor. NSAIDs decrease prostaglandin synthesis.

            • saquinavir

              saquinavir and alfuzosin both increase QTc interval. Use Caution/Monitor.

            • selpercatinib

              selpercatinib increases toxicity of alfuzosin by QTc interval. Use Caution/Monitor.

            • sertraline

              sertraline and alfuzosin both increase QTc interval. Use Caution/Monitor.

            • silodosin

              alfuzosin and silodosin both increase anti-hypertensive channel blocking. Use Caution/Monitor.

            • solifenacin

              solifenacin and alfuzosin both increase QTc interval. Use Caution/Monitor.

            • sorafenib

              sorafenib and alfuzosin both increase QTc interval. Use Caution/Monitor.

            • sotalol

              alfuzosin and sotalol both increase anti-hypertensive channel blocking. Modify Therapy/Monitor Closely. The severity and duration of hypotension following the first dose of Alfuzosin may be enhanced.

              sotalol and alfuzosin both increase QTc interval. Use Caution/Monitor.

            • St John's Wort

              St John's Wort will decrease the level or effect of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.

            • stiripentol

              stiripentol, alfuzosin. affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Stiripentol is a CYP3A4 inhibitor and inducer. Monitor CYP3A4 substrates coadministered with stiripentol for increased or decreased effects. CYP3A4 substrates may require dosage adjustment.

            • sulfasalazine

              sulfasalazine decreases effects of alfuzosin by pharmacodynamic antagonism. Use Caution/Monitor. NSAIDs decrease prostaglandin synthesis.

            • sulindac

              sulindac decreases effects of alfuzosin by pharmacodynamic antagonism. Use Caution/Monitor. NSAIDs decrease prostaglandin synthesis.

            • sunitinib

              sunitinib and alfuzosin both increase QTc interval. Use Caution/Monitor.

            • tacrolimus

              tacrolimus and alfuzosin both increase QTc interval. Use Caution/Monitor.

            • tadalafil

              tadalafil increases effects of alfuzosin by pharmacodynamic synergism. Use Caution/Monitor. Risk of hypotension.

            • tazemetostat

              tazemetostat will decrease the level or effect of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.

            • tecovirimat

              tecovirimat will decrease the level or effect of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Tecovirimat is a weak CYP3A4 inducer. Monitor sensitive CYP3A4 substrates for effectiveness if coadministered.

            • telavancin

              telavancin and alfuzosin both increase QTc interval. Use Caution/Monitor.

            • terazosin

              alfuzosin and terazosin both increase anti-hypertensive channel blocking. Use Caution/Monitor.

            • tetrabenazine

              tetrabenazine and alfuzosin both increase QTc interval. Use Caution/Monitor.

            • thioridazine

              thioridazine and alfuzosin both increase QTc interval. Use Caution/Monitor.

            • timolol

              alfuzosin and timolol both increase anti-hypertensive channel blocking. Modify Therapy/Monitor Closely.

            • tolfenamic acid

              tolfenamic acid decreases effects of alfuzosin by pharmacodynamic antagonism. Use Caution/Monitor. NSAIDs decrease prostaglandin synthesis.

            • tolmetin

              tolmetin decreases effects of alfuzosin by pharmacodynamic antagonism. Use Caution/Monitor. NSAIDs decrease prostaglandin synthesis.

            • toremifene

              toremifene and alfuzosin both increase QTc interval. Use Caution/Monitor.

            • trandolapril

              trandolapril, alfuzosin. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Exaggerated first dose hypotensive response.

            • trimipramine

              trimipramine and alfuzosin both increase QTc interval. Use Caution/Monitor.

            • triptorelin

              triptorelin and alfuzosin both increase QTc interval. Use Caution/Monitor.

            • vandetanib

              vandetanib and alfuzosin both increase QTc interval. Use Caution/Monitor.

            • vardenafil

              vardenafil and alfuzosin both increase QTc interval. Use Caution/Monitor.

            • vemurafenib

              vemurafenib and alfuzosin both increase QTc interval. Use Caution/Monitor.

            • verapamil

              alfuzosin and verapamil both increase anti-hypertensive channel blocking. Use Caution/Monitor.

            • voriconazole

              voriconazole and alfuzosin both increase QTc interval. Use Caution/Monitor.

            • vorinostat

              vorinostat and alfuzosin both increase QTc interval. Use Caution/Monitor.

            • ziprasidone

              ziprasidone and alfuzosin both increase QTc interval. Use Caution/Monitor.

            • zotepine

              alfuzosin and zotepine both increase anti-hypertensive channel blocking. Use Caution/Monitor.

            Minor (55)

            • amobarbital

              amobarbital will decrease the level or effect of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.

            • aprepitant

              aprepitant will increase the level or effect of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.

            • armodafinil

              armodafinil will decrease the level or effect of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.

            • artemether/lumefantrine

              artemether/lumefantrine will decrease the level or effect of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.

            • bosentan

              bosentan will decrease the level or effect of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.

            • brimonidine

              brimonidine increases effects of alfuzosin by pharmacodynamic synergism. Minor/Significance Unknown.

            • budesonide

              budesonide will decrease the level or effect of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.

            • butabarbital

              butabarbital will decrease the level or effect of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.

            • butalbital

              butalbital will decrease the level or effect of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.

            • butcher's broom

              alfuzosin, butcher's broom. Either decreases effects of the other by Mechanism: pharmacodynamic antagonism. Minor/Significance Unknown.

            • chloroquine

              chloroquine increases toxicity of alfuzosin by QTc interval. Minor/Significance Unknown.

            • conivaptan

              conivaptan will increase the level or effect of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.

            • cortisone

              cortisone will decrease the level or effect of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.

            • cyclosporine

              cyclosporine will increase the level or effect of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.

            • darifenacin

              darifenacin will increase the level or effect of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.

            • dasatinib

              dasatinib will increase the level or effect of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.

            • dexamethasone

              dexamethasone will decrease the level or effect of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.

            • DHEA, herbal

              DHEA, herbal will increase the level or effect of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.

            • dronedarone

              dronedarone will increase the level or effect of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.

            • eslicarbazepine acetate

              eslicarbazepine acetate will decrease the level or effect of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.

            • ethanol

              alfuzosin, ethanol. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Risk of hypotension, esp. in Asian pts.

            • fluconazole

              fluconazole will increase the level or effect of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.

            • fludrocortisone

              fludrocortisone will decrease the level or effect of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.

            • fosphenytoin

              fosphenytoin will decrease the level or effect of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.

            • grapefruit

              grapefruit will increase the level or effect of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.

            • griseofulvin

              griseofulvin will decrease the level or effect of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.

            • hydrocortisone

              hydrocortisone will decrease the level or effect of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.

            • lapatinib

              lapatinib will increase the level or effect of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.

            • lumefantrine

              lumefantrine will decrease the level or effect of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.

            • marijuana

              marijuana will increase the level or effect of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.

            • methylprednisolone

              methylprednisolone will decrease the level or effect of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.

            • metronidazole

              metronidazole will increase the level or effect of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.

            • miconazole vaginal

              miconazole vaginal will increase the level or effect of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.

            • modafinil

              modafinil will decrease the level or effect of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.

            • nifedipine

              nifedipine will increase the level or effect of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.

            • nilotinib

              nilotinib will increase the level or effect of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.

            • oxcarbazepine

              oxcarbazepine will decrease the level or effect of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.

            • pentobarbital

              pentobarbital will decrease the level or effect of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.

            • phenobarbital

              phenobarbital will decrease the level or effect of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.

            • phenylephrine

              alfuzosin, phenylephrine. Either decreases effects of the other by Mechanism: pharmacodynamic antagonism. Minor/Significance Unknown.

            • phenylephrine PO

              alfuzosin, phenylephrine PO. Either decreases effects of the other by Mechanism: pharmacodynamic antagonism. Minor/Significance Unknown.

            • phenytoin

              phenytoin will decrease the level or effect of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.

            • posaconazole

              posaconazole will increase the level or effect of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.

            • prednisone

              prednisone will decrease the level or effect of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.

            • primidone

              primidone will decrease the level or effect of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.

            • quinupristin/dalfopristin

              quinupristin/dalfopristin will increase the level or effect of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.

            • rifapentine

              rifapentine will decrease the level or effect of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.

            • rufinamide

              rufinamide will decrease the level or effect of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.

            • secobarbital

              secobarbital will decrease the level or effect of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.

            • tizanidine

              tizanidine increases effects of alfuzosin by pharmacodynamic synergism. Minor/Significance Unknown. Risk of hypotension.

            • topiramate

              topiramate will decrease the level or effect of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.

            • treprostinil

              treprostinil increases effects of alfuzosin by pharmacodynamic synergism. Minor/Significance Unknown.

            • verapamil

              verapamil will increase the level or effect of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.

            • voriconazole

              voriconazole will increase the level or effect of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.

            • zafirlukast

              zafirlukast will increase the level or effect of alfuzosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.

            Previous
            Next:

            Adverse Effects

            1-10%

            Abdominal pain (1-2%)

            Back pain (1-2%)

            Brochitis (1-2%)

            Constipation (1-2%)

            Dizziness (5.7%)

            Dyspepsia (1-2%)

            Fatigue (2.7%)

            Headache (3%)

            Impotence (1-2%)

            Nausea (1-2%)

            Pharyngitis (1-2%)

            URT infection (3%)

            Sinusitis (1-2%)

            Upper respiratory infection (3%)

            Postmarketing Reports

            General disorders: Edema

            Cardiac disorders: Tachycardia, chest pain, angina pectoris in patients with pre-existing coronary artery disease, atrial fibrillation

            Gastrointestinal disorders: Diarrhea, vomiting

            Hepatobiliary disorders: Hepatocellular and cholestatic liver injury (including cases with jaundice leading to drug discontinuation)

            Upper respiratory system: Rhinitis

            Reproductive system: Priapism

            Dermatology: Rash, pruritus, urticaria, angioedema, toxic epidermal necrolysis

            Vascular disorders: Flushing

            Blood and lymphatic system disorders: Thrombocytopenia

            Previous
            Next:

            Warnings

            Contraindications

            Hypersensitivity

            Moderate to severe liver impairment

            Coadministration with potent CYP3A4 inhibitors (eg, ketoconazole, itraconazole, ritonavir) or other alpha1-blocking agents

            Cautions

            Caution in coronary artery disease, liver disease, symptomatic orthostatic hypotension or coadministration with other drugs that lower blood pressure

            May cause syncope (first-dose effect)

            Discontinue treatment if angina occurs or worsens

            Rule out prostate cancer before initiating therapy (symptoms similar)

            Priapism may occur with use

            Rule out prostate cancer prior to treatment

            Caution with renal impairment (ieg, CrCl <30 mL/min)

            Caution with history of prolonged QT syndrome (shown to prolong QT interval)

            Intraoperative floppy iris syndrome during cataract surgery reported Advise patient regarding risk of priapism

            Do not chew or crush tablets

            Not for use as antihypertensive drug

            Previous
            Next:

            Pregnancy & Lactation

            Pregnancy

            Drug is not indicated for use in women; there are no adequate data on developmental risk associated with use in pregnant women

            Animal data

            • Based on findings from animal studies, alfuzosin administered during the period of organogenesis was not teratogenic, embryotoxic or fetotoxic at up to 1200 times the MRHD of 10 mg via AUC in rats and 3 times in rabbits, via body surface area

            Lactation

            Drug is not indicated for use in women; there are no data on presence in human milk, effect on breastfed child, or on milk production

            Pregnancy Categories

            A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.

            B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.

            C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.

            D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.

            X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.

            NA: Information not available.

            Previous
            Next:

            Pharmacology

            Mechanism of Action

            Selective antagonist of postsynaptic alpha-1-adrenoceptors; blockade of adrenoreceptors in the prostate, prostatic capsule, bladder neck and prostatic urethra

            Absorption

            Bioavailability: 49%

            Peak Plasma Time: 8 hr

            Peak Plasma Concentration: 13.6 ng/mL

            AUC: 194 ng.hr/mL

            Distribution

            Protein Bound: 82-90%

            Vd: 3.2 L/kg

            Metabolism

            Hepatic P450 enzyme CYP3A4

            Elimination

            Half-life: 5-10 hr

            Excretion: Feces (69%); urine (24%)

            Previous
            Next:

            Images

            BRAND FORM. UNIT PRICE PILL IMAGE
            alfuzosin oral
            -
            10 mg tablet
            alfuzosin oral
            -
            10 mg tablet
            alfuzosin oral
            -
            10 mg tablet
            alfuzosin oral
            -
            10 mg tablet
            alfuzosin oral
            -
            10 mg tablet
            alfuzosin oral
            -
            10 mg tablet
            alfuzosin oral
            -
            10 mg tablet
            Uroxatral oral
            -
            10 mg tablet
            Uroxatral oral
            -
            10 mg tablet

            Copyright © 2010 First DataBank, Inc.

            Previous
            Next:

            Patient Handout

            Patient Education
            alfuzosin oral

            ALFUZOSIN EXTENDED-RELEASE - ORAL

            (al-FUE-zoe-sin)

            COMMON BRAND NAME(S): Uroxatral

            USES: Alfuzosin is used by men to treat the symptoms of an enlarged prostate (benign prostatic hyperplasia-BPH). It does not shrink the prostate, but it works by relaxing the muscles in the prostate and the bladder. This helps to relieve symptoms of BPH such as difficulty in beginning the flow of urine, weak stream, and the need to urinate often or urgently (including during the middle of the night).Alfuzosin belongs to a class of drugs known as alpha blockers.Do not use this medication to treat high blood pressure.

            HOW TO USE: Read the Patient Information Leaflet if available from your pharmacist before you start taking alfuzosin and each time you get a refill. If you have any questions, ask your doctor or pharmacist.Take this medication by mouth as directed by your doctor, usually once daily after a meal. This medication works best when taken with food. Taking alfuzosin on an empty stomach may make it not work as well.Do not crush or chew extended-release tablets. Doing so can release all of the drug at once, increasing the risk of side effects. Also, do not split the tablets unless they have a score line and your doctor or pharmacist tells you to do so. Swallow the whole or split tablet without crushing or chewing.Alfuzosin may cause a sudden drop in your blood pressure, which could lead to dizziness or fainting, usually within a few hours after you take it. This risk is higher when you first start taking this drug or if you restart treatment after you stop taking it. During these times, avoid situations where you may be injured if you faint.To avoid injury from dizziness or fainting, your doctor may tell you to take your first dose of alfuzosin with food at bedtime so that your body can get used to its effects.Take this medication regularly to get the most benefit from it. To help you remember, take it after the same meal each day.Tell your doctor if your condition does not improve or if it worsens.

            SIDE EFFECTS: Dizziness or lightheadedness may occur. If either of these effects persists or worsens, tell your doctor or pharmacist promptly.To reduce the risk of dizziness and lightheadedness, get up slowly when rising from a sitting or lying position.Remember that your doctor has prescribed this medication because he or she has judged that the benefit to you is greater than the risk of side effects. Many people using this medication do not have serious side effects.Get medical help right away if you have any very serious side effects, including: severe dizziness, fainting, fast/irregular heartbeat, chest pain.Rarely, males may have a painful or prolonged erection lasting 4 or more hours. If this occurs, stop using this drug and get medical help right away, or permanent problems could occur.A very serious allergic reaction to this drug is rare. However, get medical help right away if you notice any symptoms of a serious allergic reaction, including: rash, itching/swelling (especially of the face/tongue/throat), severe dizziness, trouble breathing.This is not a complete list of possible side effects. If you notice other effects not listed above, contact your doctor or pharmacist.In the US -Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088 or at www.fda.gov/medwatch.In Canada - Call your doctor for medical advice about side effects. You may report side effects to Health Canada at 1-866-234-2345.

            PRECAUTIONS: Before taking alfuzosin, tell your doctor or pharmacist if you are allergic to it; or if you have any other allergies. This product may contain inactive ingredients, which can cause allergic reactions or other problems. Talk to your pharmacist for more details.Before using this medication, tell your doctor or pharmacist your medical history, especially of: liver disease, kidney disease, heart problems (such as chest pain/angina, heart attack), low blood pressure, certain eye problems (cataracts, glaucoma).Alfuzosin may cause a condition that affects the heart rhythm (QT prolongation). QT prolongation can rarely cause serious (rarely fatal) fast/irregular heartbeat and other symptoms (such as severe dizziness, fainting) that need medical attention right away.The risk of QT prolongation may be increased if you have certain medical conditions or are taking other drugs that may cause QT prolongation. Before using alfuzosin, tell your doctor or pharmacist of all the drugs you take and if you have any of the following conditions: certain heart problems (heart failure, slow heartbeat, QT prolongation in the EKG), family history of certain heart problems (QT prolongation in the EKG, sudden cardiac death).Low levels of potassium or magnesium in the blood may also increase your risk of QT prolongation. This risk may increase if you use certain drugs (such as diuretics/"water pills") or if you have conditions such as severe sweating, diarrhea, or vomiting. Talk to your doctor about using alfuzosin safely.This drug may make you dizzy. Alcohol or marijuana (cannabis) can make you more dizzy. Do not drive, use machinery, or do anything that needs alertness until you can do it safely. Limit alcoholic beverages. Talk to your doctor if you are using marijuana (cannabis).Before having surgery (including cataract/glaucoma eye surgery), tell your doctor or dentist if you are taking or have ever taken this medication, and about all the other products you use (including prescription drugs, nonprescription drugs, and herbal products).Older adults may be more sensitive to the side effects of this drug, especially dizziness and low blood pressure when getting up from a sitting or lying position, and QT prolongation (see above). These side effects can also increase the risk of falling.During pregnancy, this medication should be used only when clearly needed. Discuss the risks and benefits with your doctor.It is unknown if this medication passes into breast milk. Consult your doctor before breast-feeding.

            DRUG INTERACTIONS: Drug interactions may change how your medications work or increase your risk for serious side effects. This document does not contain all possible drug interactions. Keep a list of all the products you use (including prescription/nonprescription drugs and herbal products) and share it with your doctor and pharmacist. Do not start, stop, or change the dosage of any medicines without your doctor's approval.Some products that may interact with this drug include: other alpha blocker drugs (such as prazosin, terazosin).If you are also taking a drug to treat erectile dysfunction-ED or pulmonary hypertension (such as sildenafil, tadalafil), your blood pressure may get too low which can lead to dizziness or fainting. Your doctor may need to adjust your medications to minimize this risk.Other medications can affect the removal of alfuzosin from your body, which may affect how alfuzosin works. Examples include azole antifungals (such as itraconazole, ketoconazole), boceprevir, clarithromycin, cobicistat, HIV protease inhibitors (such as lopinavir, ritonavir), mifepristone, nefazodone, ribociclib, telaprevir, telithromycin, among others.

            OVERDOSE: If someone has overdosed and has serious symptoms such as passing out or trouble breathing, call 911. Otherwise, call a poison control center right away. US residents can call their local poison control center at 1-800-222-1222. Canada residents can call a provincial poison control center. Symptoms of overdose may include: severe dizziness, fainting.

            NOTES: Do not share this medication with others.Laboratory and/or medical tests (such as prostate exams, blood pressure) should be performed periodically to monitor your progress or check for side effects. Consult your doctor for more details.

            MISSED DOSE: If you miss a dose, take it as soon as you remember. If it is near the time of the next dose, skip the missed dose. Take your next dose at the regular time. Do not double the dose to catch up.

            STORAGE: Store at room temperature away from light and moisture. Do not store in the bathroom. Keep all medications away from children and pets.Do not flush medications down the toilet or pour them into a drain unless instructed to do so. Properly discard this product when it is expired or no longer needed. Consult your pharmacist or local waste disposal company.

            Information last revised June 2021. Copyright(c) 2021 First Databank, Inc.

            IMPORTANT: HOW TO USE THIS INFORMATION: This is a summary and does NOT have all possible information about this product. This information does not assure that this product is safe, effective, or appropriate for you. This information is not individual medical advice and does not substitute for the advice of your health care professional. Always ask your health care professional for complete information about this product and your specific health needs.

            Previous
            Next:

            Formulary

            FormularyPatient Discounts

            Adding plans allows you to compare formulary status to other drugs in the same class.

            To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.

            Adding plans allows you to:

            • View the formulary and any restrictions for each plan.
            • Manage and view all your plans together – even plans in different states.
            • Compare formulary status to other drugs in the same class.
            • Access your plan list on any device – mobile or desktop.

            The above information is provided for general informational and educational purposes only. Individual plans may vary and formulary information changes. Contact the applicable plan provider for the most current information.

            Tier Description
            1 This drug is available at the lowest co-pay. Most commonly, these are generic drugs.
            2 This drug is available at a middle level co-pay. Most commonly, these are "preferred" (on formulary) brand drugs.
            3 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs.
            4 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
            5 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
            6 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
            NC NOT COVERED – Drugs that are not covered by the plan.
            Code Definition
            PA Prior Authorization
            Drugs that require prior authorization. This restriction requires that specific clinical criteria be met prior to the approval of the prescription.
            QL Quantity Limits
            Drugs that have quantity limits associated with each prescription. This restriction typically limits the quantity of the drug that will be covered.
            ST Step Therapy
            Drugs that have step therapy associated with each prescription. This restriction typically requires that certain criteria be met prior to approval for the prescription.
            OR Other Restrictions
            Drugs that have restrictions other than prior authorization, quantity limits, and step therapy associated with each prescription.
            Additional Offers
            Email to Patient

            From:

            To:

            The recipient will receive more details and instructions to access this offer.

            By clicking send, you acknowledge that you have permission to email the recipient with this information.

            Email Forms to Patient

            From:

            To:

            The recipient will receive more details and instructions to access this offer.

            By clicking send, you acknowledge that you have permission to email the recipient with this information.

            Previous
            Medscape prescription drug monographs are based on FDA-approved labeling information, unless otherwise noted, combined with additional data derived from primary medical literature.